Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

Enrolling by invitation

Conditions studied: Glioblastoma (GBM)

In brief

The goal of this sub-study of the RESTORE trial is to identify biomarkers associated with tumor hypoxia, identify biomarkers that differentiate pseudoprogression from true progression, and correlate biomarkers with clinical outcomes.

Key facts

Study ID

NCT07417774

Run by

NuvOx LLC

People needed

40

Starts

2025-12-08

Expected to finish

2030-12-01

Last updated by the study team

2026-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must be enrolled in the RESTORE study (NCT03862430) and provide written informed consent for the RESTORE LB sub-study

Where it is running

• Center for Neurosciences — Tucson, Arizona, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Saint Luke's Cancer Institute — Kansas City, Missouri, United States
• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.